HIV remains a major global health challenge, partly because the virus mutates rapidly, making vaccine development extremely difficult. Scientists at Scripps Research aim to accelerate progress by acquiring advanced high-performance computing and AI technology, funded by a $1.1 million investment from the NIH-supported Scripps Consortium for HIV/AIDS Vaccine Development.
The new AI infrastructure will greatly speed up analysis of vast clinical trial datasets and allow researchers to evaluate millions of potential vaccine designs, compared to only dozens previously. This shift enables “smart prediction” rather than slow trial-and-error, helping identify the most promising candidates more efficiently.
Researchers hope ultimately to develop a long-lasting, single-dose HIV vaccine that adapts to viral mutations, but in the near term they are designing a series of vaccines that evolve alongside the virus. The upgraded computational power—4–5 times faster than current systems—will allow the team to rapidly analyze vaccine-induced antibodies, model interactions with the virus, and refine each next-generation vaccine.
AI models will be trained on historical clinical trial data and enhanced using StepwiseDesign, a method that mimics how the immune system gradually improves antibodies. The approach has already yielded success: the team identified a rare, HIV-neutralizing antibody in someone never infected with HIV, proving that some people naturally carry precursor antibodies capable of maturing into broadly protective forms.
With multiple HIV vaccine candidates now in human trials, the enhanced computational capabilities are expected to dramatically speed up vaccine design, potentially shortening the timeline toward an effective HIV vaccine.